Cardiol Therapeutics Inc. (CRDL)
Cardiol Therapeutics Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Oakville, ON, CA. The stock last traded at $1.71, down 1.16% on the session, giving a market capitalisation of $197.1M. On trailing twelve-month figures it carries a trailing P/E of -7.06, a net margin of 0.0%. Its beta of 0.52 implies it has historically moved less than the broad market.
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
Cardiol Therapeutics Inc. is most often compared with the following Healthcare names: